Showing results (2781-2790 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|December 21, 2010
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancerDirk Strumberg, Beate Schultheis, M E Scheulen, et al.Investigational New Drugs|December 21, 2010
Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochlorideKathryn A Skelding, Richard D Barry, Darren R ShafrenInvestigational New Drugs|February 19, 2011
In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83Xiangrui Liu, Frankie Lam, Shenhua Shi, et al.Investigational New Drugs|February 19, 2011
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcomaSteven J O'Day, Anna C Pavlick, Mark R Albertini, et al.Investigational New Drugs|November 25, 2010
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patientsDok Hyun Yoon, Min-Hee Ryu, Baek-Yeol Ryoo, et al.Investigational New Drugs|December 15, 2010
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression modelAngelica Linnea Quartino, Lena E Friberg, Mats O KarlssonInvestigational New Drugs|December 15, 2010
The DAC system and associations with acute leukemias and myelodysplastic syndromesGesine Bug, Oliver G OttmannInvestigational New Drugs|October 28, 2010
A phase I study of temsirolimus and metformin in advanced solid tumoursMary J MacKenzie, Scott Ernst, Craig Johnson, et al.Investigational New Drugs|October 28, 2010
Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cellsEun-Taex Oh, Moon-Taek Park, Bo-Hwa Choi, et al.Investigational New Drugs|January 19, 2011
Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell linesYakini Brandy, Innocent Ononiwu, Dolapo Adedeji, et al.Pageof 372